Sign In

Search |

Add/Edit My Facility

Viral Vector Core Facility

Subscribe to this Core


Facility Resources

Viral Vector

Facility Address

Sanford Burnham Prebys Medical Discovery Institute

10901 N Torrey Pines Road

La Jolla,, CA 92037

United States

https://sbpdiscovery.org/research/shared-resources/viral-vectors/

Google Maps Location

cite this facility

Primary Contact:

Chunteng Huang

Additional Citation Identifiers

1S10OD036254-012P30CA030199-29

Facility Details

The SBP Viral Vector Core Facility provides state-of-the-art viral vector-based gene/shRNA delivery technology. Its portfolio ranges from lentivirus, retrovirus, adenovirus, adeno-associated virus, zika virus, coronavirus, sindbis virus and vesicular stomatitis virus products as well as customized "The Works" viral vector construction and swapping service packages. There are over 50 ready-to-transduce reporter viruses available for live cell imaging and 2D/3D cell-based assays. For custom virus production, we can achieve high-titer, top quality viral particles suitable for in vitro and in vivo studies. The automated mini-scale preparations of vector plasmids and viruses in 96-well format can immediately allow downstream viral array screening. The core also extends technical expertise in non-viral nanoparticles which includes large extracellular vesicles and exosome purification, analysis and engineering.

Funding Info

NIH - 04/06/2024 - Beckman Coulter Biomek i7 Hybrid automated workstation

is_active:

No

budget_end:

03/31/2025

date_added:

04/06/2024

agency_code:

NIH

fiscal_year:

2024

project_num:

1S10OD036254-01

award_amount:

$594,187.00

budget_start:

04/01/2024

org_name:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

org_state:

CA

org_country:

UNITED STATES

org_zipcode:

920371005

primary_duns:

020520466

abstract_text:

PROJECT SUMMARY Sanford Burnham Prebys Medical Discovery Institute (SBP) has 40 research labs specializing in cancer, children’s health, stem cells, degenerative diseases of aging, as well as infectious and other diseases. Many recent advances in medical research and healthcare rely on the discovery of novel therapeutic targets. Recently, advances in functional genomic technologies have provided an unprecedented opportunity to understand fundamental mechanisms underlying diseases initiation, progression, and relapse. Thus, these technologies hold great promise in the identification of novel targets and innovative treatments. In order to remain cutting-edge, the SBP Functional Genomics Core Facility seeks funding to acquire the Beckman Coulter Biomek i7 Hybrid automated workstation. This fully automated system, with 8 independent pipettes and interchangeable 96 and 384-multichannel liquid handling platforms, will replace our existing outdated, underperforming Hamilton Microlab STAR (2005 model year, 96-well platform) and Agilent Bravo (2010 model year, 384-well platform) equipment. Even after expensive software and hardware upgrades, both the Hamilton STAR and Agilent Bravo models will still fall short of automating the desired library preparation and screening workflows demanded by the NIH-funded projects that are currently being supported by our core facility. A key part of this enhancement is the production and screening of large-scale arrayed CRISPR libraries, which enables a wide variety of new scientific approaches not possible with pooled or small-scale arrayed CRISPR library analysis. In contrast to the Hamilton STAR and Agilent Bravo, the new Biomek i7 enables streamlined automation of multiple continuous pipelines and mitigates capacity limitations. Designated pipelines include high- throughput production of bacteria, viral vector plasmids, recombinant viruses, and mammalian cell cultures, as well as cell-based phenotypic screening and assay processing, which can be accomplished on a 96/384-well platform. This application is supported by eight major SBP users with active NIH-funded projects. As stated in the application, the projects of all eight major users - together accounting for 77% of the Biomek i7’s available use time (AUT) - will greatly benefit from the Biomek i7 automation to advance their proposed studies in diverse human disease research topics including cancer, aging, muscular dystrophy, Alzheimer’s disease and related dementia, and COVID-19.

project_title:

Beckman Coulter Biomek i7 Hybrid automated workstation

contact_pi_name:

HUANG, CHUN-TENG

total_cost:

$594,187.00

NIH - 05/25/2024 - Cancer Genome & Epigenetics

is_active:

No

budget_end:

04/30/2025

date_added:

05/25/2024

agency_code:

NIH

fiscal_year:

2024

project_num:

5P30CA030199-43

award_amount:

$56,413.00

budget_start:

05/01/2024

org_name:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

org_state:

CA

org_country:

UNITED STATES

org_zipcode:

920371005

primary_duns:

020520466

abstract_text:

The overall goals of the Cancer Genome & Epigenetics (CGE) Program (formerly Tumor Initiation and Maintenance Program) are to identify the cells that give rise to tumors and the signals that allow these cells to expand uncontrollably, and to use this information to develop more effective approaches to treating human cancer.

project_title:

Cancer Genome & Epigenetics

contact_pi_name:

ADAMS, PETER D.

total_cost:

$56,413.00

Facility Policies

Services are offerred outside of

Consulting is offerred outside of Sanford Burnham Prebys Medical Discovery Institute

Last Updated: 10/02/2026